PFEPFIZER INC

NYSE pfizer.com


$ 27.42 $ -0.57 (-2.04 %)    

Wednesday, 26-Jun-2024 15:59:59 EDT
QQQ $ 478.80 $ 0.99 (0.21 %)
DIA $ 391.21 $ 0.22 (0.06 %)
SPY $ 545.04 $ 0.68 (0.12 %)
TLT $ 93.14 $ -1.35 (-1.43 %)
GLD $ 212.60 $ -1.98 (-0.92 %)
$ 27.42
$ 27.89
$ 27.40 x 100
$ 27.43 x 100
$ 27.07 - $ 27.92
$ 24.83 - $ 35.80
30,197,963
na
156.21B
$ 0.57
nm
TBD
na
na ($ 0.06)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-22-2024 12-31-2023 10-K
3 11-08-2023 10-01-2023 10-Q
4 08-09-2023 07-02-2023 10-Q
5 05-10-2023 04-02-2023 10-Q
6 02-23-2023 12-31-2022 10-K
7 11-09-2022 10-02-2022 10-Q
8 08-10-2022 07-03-2022 10-Q
9 05-11-2022 04-03-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-12-2021 10-03-2021 10-Q
12 08-12-2021 07-04-2021 10-Q
13 05-13-2021 04-04-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-27-2020 10-Q
16 08-06-2020 06-28-2020 10-Q
17 05-07-2020 03-29-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-07-2019 09-29-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-09-2018 07-01-2018 10-Q
25 05-10-2018 04-01-2018 10-Q
26 02-22-2018 12-31-2017 10-K
27 11-09-2017 10-01-2017 10-Q
28 08-10-2017 07-02-2017 10-Q
29 05-11-2017 04-02-2017 10-Q
30 02-23-2017 12-31-2016 10-K
31 11-10-2016 10-02-2016 10-Q
32 08-11-2016 07-03-2016 10-Q
33 05-12-2016 04-03-2016 10-Q
34 02-29-2016 12-31-2015 10-K
35 11-05-2015 09-27-2015 10-Q
36 08-06-2015 06-28-2015 10-Q
37 05-07-2015 03-29-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-06-2014 09-28-2014 10-Q
40 08-07-2014 06-29-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 whats-going-on-with-pfizer-shares-wednesday

Pfizer Inc. (NYSE: PFE) is experiencing notable stock movement on Wednesday afternoon. Here's what you need to know.

Core News & Articles

- Reuters

Core News & Articles

- Reuters

 pfizer-reports-15-decrease-in-patient-enrollment-in-phase-3-ulcerative-colitis-trial-enrollment-drops-from-912-to-772-patients-trial-active-but-not-recruiting-primary-completion-date-revised-to-july-20-2026

https://clinicaltrials.gov/study/NCT03950232

 why-is-moderna-stock-trading-lower-on-wednesday

The CDC's Advisory Committee on Immunization Practices is set to discuss recommendations for RSV, influenza, and COVID-19 v...

 cantor-fitzgerald-reiterates-overweight-on-pfizer-maintains-45-price-target

Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.

 supreme-court-backs-pharmaceutical-giants-in-iraq-terrorism-funding-case

The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism i...

 uk-chooses-pfizer-over-gsk-for-multi-million-dose-rsv-vaccine-contract

Pfizer secures a UK contract to supply millions of doses of its Abrysvo RSV vaccine, surpassing GSK's bid. The agreement in...

Core News & Articles

GSK Plc has lost out to Pfizer Inc. on a contract to supply millions of doses of its blockbuster RSV vaccine to the UK in a set...

 gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatments

Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...

 fda-approves-expanded-use-for-sareptas-rare-muscular-dystrophy-gene-therapy

The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older w...

 industry-groups-back-gsks-effort-to-halt-70000-lawsuits-associated-with-heartburn-drug-zantac-caused-cancer

GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threat...

 cantor-fitzgerald-reiterates-overweight-on-pfizer-maintains-45-price-target

Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.

 supreme-court-upholds-2017-tax-on-foreign-profits-for-us-businesses

US Supreme Court upholds 2017 tax on foreign business income, citing Congress' constitutional power to tax. Justices Kavana...

 palantir-oracle-pfizer-chiefs-lobby-us-lawmakers-for-israels-support-amid-hamas-attack-hostage-crisis

CEOs of Palantir, Oracle, and Pfizer lobbied US senators for support of Israel during Gaza invasion and discussed solutions for...

 covid-19-pharma-stars-continue-their-quest-to-set-new-standards-in-cancer-treatment

AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its bloc...

 fda-approves-mercks-pneumococcal-vaccine-as-first-shot-designed-for-adults

The FDA has approved Merck's Capvaxive, the first pneumococcal conjugate vaccine for adults, protecting against 21 strains ...

 cantor-fitzgerald-reiterates-overweight-on-pfizer-maintains-45-price-target

Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.